Search alternatives:
"50 ppm decrease" » "50 _ decrease" (Expand Search), "50 pa decreased" (Expand Search), "50 026 decrease" (Expand Search), "5 ppm decrease" (Expand Search)
"50 nn decrease" » "50 _ decrease" (Expand Search), "50 gy decreased" (Expand Search), "50 b1 decreased" (Expand Search), "50 ns decrease" (Expand Search), "50 ng decrease" (Expand Search), "50 n decrease" (Expand Search)
"5 a decrease" » "5 _ decrease" (Expand Search), "5 _ decreased" (Expand Search), "5 _ decreases" (Expand Search)
Showing 1 - 20 results of 48 for search '(("50 ppm decrease") OR ((("50 nn decrease") OR ((("_ mean decrease") OR ("5 a decrease"))))))', query time: 0.22s Refine Results
  1. 1
    Descriptives of the study sample, N = 451.

    Descriptives of the study sample, N = 451. by Orrin D. Ware (14829115)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 2
    Cronbach’s alpha and means the stigma of Suicide Scale Short Form (SOSS-SF).

    Cronbach’s alpha and means the stigma of Suicide Scale Short Form (SOSS-SF). by Orrin D. Ware (14829115)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Number of samples tested, seropositivity and anti-mumps antibody titers in different groups.

    Number of samples tested, seropositivity and anti-mumps antibody titers in different groups. by Zixia Qian (21474969)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Results of multifactorial log-binomial regression models of seropositivity for IgG antibodies against mumps in healthy populations.

    Results of multifactorial log-binomial regression models of seropositivity for IgG antibodies against mumps in healthy populations. by Zixia Qian (21474969)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Trends in anti-mumps IgG attenuation in 1-dose and 2-dose vaccine groups after excluding samples vaccinated for >192 months and >36 months, respectively.

    Trends in anti-mumps IgG attenuation in 1-dose and 2-dose vaccine groups after excluding samples vaccinated for >192 months and >36 months, respectively. by Zixia Qian (21474969)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Anti-mumps antibody titers, Seropositivity, and IgG Decay.

    Anti-mumps antibody titers, Seropositivity, and IgG Decay. by Zixia Qian (21474969)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Histograms of mean anti-mumps antibody titers and seropositivity by vaccine dose and age (0-25 years).

    Histograms of mean anti-mumps antibody titers and seropositivity by vaccine dose and age (0-25 years). by Zixia Qian (21474969)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Baseline characteristics of study participants.

    Baseline characteristics of study participants. by Zixia Qian (21474969)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    The numerical data used in this study.

    The numerical data used in this study. by Zixia Qian (21474969)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Heat map of per capita GDP in Guangdong province, and seroprevalence of Guangzhou and Heyuan.

    Heat map of per capita GDP in Guangdong province, and seroprevalence of Guangzhou and Heyuan. by Zixia Qian (21474969)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Map of sampled sites created using ArcGIS software.

    Map of sampled sites created using ArcGIS software. by Joseph Kagabo (20405114)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 12
    Data correlated and used in the study.

    Data correlated and used in the study. by Joseph Kagabo (20405114)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 13
    Glucose-lowering efficacy.

    Glucose-lowering efficacy. by Sungmin Kim (628527)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  14. 14
    eGFR values and mean eGFR change after the use of dulaglutide.

    eGFR values and mean eGFR change after the use of dulaglutide. by Sungmin Kim (628527)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  15. 15
    Fig 3 -

    Fig 3 - by Joseph Kagabo (20405114)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 16
    Fig 2 -

    Fig 2 - by Joseph Kagabo (20405114)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 17
    Summary statistics of physico-chemical properties across Rwandan water bodies.

    Summary statistics of physico-chemical properties across Rwandan water bodies. by Joseph Kagabo (20405114)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 18
    Baseline characteristics.

    Baseline characteristics. by Sungmin Kim (628527)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  19. 19
    The incidence rate of progression from microalbuminuria to proteinuria with dulaglutide use.

    The incidence rate of progression from microalbuminuria to proteinuria with dulaglutide use. by Sungmin Kim (628527)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  20. 20
    Clinical factors affecting renal response to dulaglutide.

    Clinical factors affecting renal response to dulaglutide. by Sungmin Kim (628527)

    Published 2022
    Subjects:
    Save to List
    Saved in:

Search Tools: